Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01052532 · ClinicalTrials.gov registry record
Molecular Mechanisms of Mitral Regurgitation-Aim 2
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 65
- Enrollment target
NCT01052532: Completed study, sponsored by University of Alabama at Birmingham.
NCT01052532 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01052532 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 65 participants
- Enrollment target
Study Summary
The investigators hypothesize that MR in humans is characterized by adrenergic overdrive, reactive nitrogen species, and an antifibrotic phenotype that relate to the severity of adverse LV remodeling prior to surgery and outcome after valve repair.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2005-06 |
| Est. Completion | 2010-11 |
What the finished NCT01052532 record still lists
NCT01052532 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 65 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01052532 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01052532 about?
NCT01052532 is a clinical study titled "Molecular Mechanisms of Mitral Regurgitation-Aim 2". The investigators hypothesize that MR in humans is characterized by adrenergic overdrive, reactive nitrogen species, and an antifibrotic phenotype that relate to the severity of adverse LV remodeling prior to surgery and outcome after valve repair.
What is the current status of trial NCT01052532?
This trial is currently completed. The enrollment target is 65 participants. The study started on 2005-06. Estimated completion is 2010-11.
Who is sponsoring clinical trial NCT01052532?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia